title: Immunohistochemical detection of CD 95 (Fas) & Fas ligand (Fas-L) in plasma cells of multiple myeloma and its correlation with survival.
abstract: Multiple myeloma (MM) is a malignant disease resulting from an uncontrolled proliferation of a neoplastic plasma cell clone in the bone marrow, which might also be induced by the loss of control on apoptosis. Fas ligand (Fas-L), a member of the tumor necrosis factor family, induces apoptosis mediated via its transmembrane death receptor Fas (Apo-1/CD95) antigen. In the present study, immunostaining was performed on the initial diagnostic bone marrow biopsies of 36 MM patients (1 stage I, 5 stage II, 30 stage III), to evaluate the distribution of Fas receptor and Fas-L on malignant plasma cells. Both Fas and Fas-L were positive in 13 cases and negative in 3, whereas 10 cases were Fas-negative, Fas-L-positive and 10 were Fas-positive, Fas-L-negative. Although no association was found between the expression of Fas receptor or Fas-L and overall survival, Fas-L positivity was significantly associated with a shorter event-free survival (p = 0.0335). In this study, it has been shown that the expression of Fas-L, in malignant plasma cells of myeloma patients significantly shortens the event-free survival, indicating that the defect in apoptosis might be associated with disease progression in MM.
authors.affiliation: Department of Pathology, Ege University Faculty of Medicine, Bornova, Izmir 35100, Turkey. mine.hekimgil@ege.edu.tr
authors.forename: Mine
authors.initials: M
authors.lastname: Hekimgil
authors.forename: Seçkin
authors.initials: S
authors.lastname: Cağirgan
authors.forename: Mustafa
authors.initials: M
authors.lastname: Pehlivan
authors.forename: Başak
authors.initials: B
authors.lastname: Doğanavşargil
authors.forename: Murat
authors.initials: M
authors.lastname: Tombuloğlu
authors.forename: Saliha
authors.initials: S
authors.lastname: Soydan
mesh_terms: D000328:Adult; D000368:Aged; D001706:Biopsy; D053222:Fas Ligand Protein; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis* / Q000378:metabolism; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D010950:Plasma Cells / Q000473:pathology*; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D048069:Tumor Necrosis Factors / Q000032:analysis* / Q000378:metabolism; D019014:fas Receptor / Q000032:analysis* / Q000378:metabolism
chemical_list: C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D048069:Tumor Necrosis Factors; D019014:fas Receptor